The use of angiotensin receptor blocker losartan in the combinational therapy of arterial hypertension


Blockade of renin-angiotensin systems is one problem in the treatment of arterial hypertension. Resistant hypertension and patients with high cardiovascular
risk demand frequently use of combination therapy. The efficiency of combined therapy losartan plus hydrochlorothiazide at patients
with arterial hypertension was studied in several large clinical multicentre randomized studies. It is proved high efficiency and safety of this combination

About the authors

N Sh Zagidullin

Sh Z Zagidullin


  1. Беленков Ю.Н. и рабочая группа исследователей ЭПИГРАФ-2. Эналаприл плюс Индапамид в лечение АГ: оценка эффективности и безопасности Рациональной Фармакотерапии. Применение нефиксированной комбинации Эналаприла и Индапамида (Энзикс). Дизайн и основные результаты исследования ЭПИГРАФ-2. Сердце. 2005; 4 (5): 277-86.
  2. Лопатин Ю.М. Фиксированные низкодозовые комбинации антигипертензивных средств с позиции препаратов первого выбора для лечения артериальной гипертонии. Сердце. 2006; 4 (3): 113-55.
  3. Фомин И.В. Артериальная гипертония в Российской Федерации - последние десять лет. Что дальше? Сердце. 2007; 6 (3): 120-3.
  4. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
  5. Christensen DB, Williams B, Goldberg HI et al. Assessing compliance to antihypertensive medications using computer-based pharmacy records. Med Care 1999; 35 (11): 1164-70.
  6. Coca A, Sobrino J, Soler J et al. Trough-to-peak ratio, smoothness index, and circadian blood pressure profile after treatment with once-daily fixed combination of losartan 100 and hydrochlorothiazide 25 in essential hypertension. J Cardiovasc Pharmacol 2002; 39: 824-33.
  7. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part2: short-term reductions in blood pressure: Overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-8.
  8. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
  9. Flack JM, Saunders E, Gradman A et al. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther 2001; 23: 1193-208.
  10. F?rster A, Smolka W, Jung C et al. Fixed-dose combination of losartan/hydrochlorothiazide 100mg/25mg: safety and efficacyon office and 24-h blood pressure. MMW Fortschr Med 2007; 149: 111-8.
  11. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.
  12. Gradman AH, Brady WE, Gazdick LP et al. A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12,5 mg in the treatment of moderate-to-severe essential hypertension. Clin Ther 2002; 24: 1049-61.
  13. Lakshman MR, Reda DJ, Materson BJ et al. Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 1999; 159: 551-8.
  14. Longobardi G, Corbi G, Cacciatore F et al. Effect of Losartan in Treatment of Exercise-Induced Myocardial Ischemia Am J Cardiol 2007; 100: 1517-21.
  15. Lubsen J, Wagener G, Kirwan B et al. ACTION (A Coronary disease Trial Investigating Outcome with Niefedipine GITS) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005; 23: 642-8.
  16. Moen MD, Wagstaff AJ. Losartan: a review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy. Drugs 2005; 65: 2657-74.
  17. Naidoo DP, Sareli P, Marin F et al. Increased efficacy and tolerability with losartan plus hydrochlorothiazide in patients with uncontrolled hypertension and therapy-related symptoms receiving two monotherapies. Adv Ther 1999; 16: 187-99.
  18. Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensiveagents on cardiovascular events in patients with coronary diseaseand normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-25.
  19. Okano Y, Tamura K, Kuji T et al. Effects of Angiotensin II Receptor Blockers on Relationships Between 24-Hour Blood Pressure, Autonomic Function, and Health-Related QOL. Clinical and Experimental Hypertension 2009; 31: 250-8.
  20. Oparil S, Aurup P, Snavely D et al. Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension. Am J Cardiol 2001; 87: 721-6.
  21. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patinets with symptomatic heart failure randomized trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-7.
  22. Soffer BA, Wright JrJT, Pratt JH et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26: 112-7.
  23. Weir MR, Moser M. Diuretics and beta-blockers: is there a risk for dyslipidemia? Am Heart J 2000; 139: 174-83.



Abstract - 147


Article Metrics

Metrics Loading ...




  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies